Patents by Inventor Yoshio Ogino

Yoshio Ogino has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10370372
    Abstract: To provide a compound having an inhibitory activity for an androgen receptor. A fused pyrimidine compound represented by the following formula (I) or a pharmaceutically acceptable thereof (in the formula, X, Y, Z, R1, and R2 are as defined in the specification).
    Type: Grant
    Filed: November 25, 2016
    Date of Patent: August 6, 2019
    Assignee: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Kazuhisa Minamiguchi, Shigeo Okajima, Takahiro Asai, Masanori Asai, Yoshio Ogino
  • Patent number: 10357412
    Abstract: A stretcher has a rectangle-shaped subject placement portion on which a subject is placed and a carrying device carrying the subject placement portion, comprising: a switching part switched to any one of at least two states; and a switching device switching a state of the switching part in accordance with a supplied gas pressure. The at least two states include a state in which the switching part prevents movement of the subject placement portion and a state in which the switching part allows the movement.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: July 23, 2019
    Assignees: FUJIDENOLO CO., LTD., MEDIPOLIS MEDICAL RESEARCH INSTITUTE
    Inventors: Takeshi Arimura, Mitsugi Matsuyama, Yoshio Hishikawa, Takashi Ogino, Hideki Miyazaki, Keiichi Noma, Akari Sakuragi
  • Patent number: 10322051
    Abstract: An operating table includes a patient placement table for placing and securing a patient in a required posture; a main body for supporting the patient placement table; engaging pieces for removably coupling the patient placement table to the main body; and a motor for rotating the patient placement table with a head-feet direction of the patient as a rotation axis to hold the patient placement table at any given rotation angle.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: June 18, 2019
    Assignees: FUJIDENOLO CO., LTD, MEDIPOLIS MEDICAL RESEARCH INSTITUTE
    Inventors: Takeshi Arimura, Mitsugi Matsuyama, Takashi Ogino, Yoshio Hishikawa, Hideki Miyazaki, Yoshitaka Taguchi, Keiichi Noma
  • Publication number: 20180312505
    Abstract: To provide a compound having an inhibitory activity for an androgen receptor. A fused pyrimidine compound represented by the following formula (I) or a pharmaceutically acceptable thereof (in the formula, X, Y, Z, R1, and R2 are as defined in the specification).
    Type: Application
    Filed: November 25, 2016
    Publication date: November 1, 2018
    Applicant: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Kazuhisa MINAMIGUCHI, Shigeo OKAJIMA, Takahiro ASAI, Masanori ASAI, Yoshio OGINO
  • Patent number: 9145414
    Abstract: The present invention provides a compound represented by the following general formula (I) or a salt thereof which has a Syk inhibitory effect (in the formula R1 represents a hydrogen atom or an optionally substituted C1-C6 alkyl group; A represents a hydrogen atom, an optionally substituted C1-C8 alkyl group, an optionally substituted C2-C6 alkenyl group, an optionally substituted C2-C6 alkynyl group, an optionally substituted C3-C10 cycloalkyl group, an optionally substituted C6-C14 aromatic hydrocarbon group, an optionally substituted 4- to 10-membered unsaturated heterocyclic group, or an optionally substituted 4- to 10-membered saturated heterocyclic group, or optionally forms a 4- to 10-membered unsaturated heterocyclic ring or a 4- to 10-membered saturated heterocyclic ring together with R1 and the nitrogen atom bonded thereto; R2 represents a hydrogen atom or an optionally substituted C1-C6 alkyl group; and B represents an optionally substituted unsaturated heterocyclic group).
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: September 29, 2015
    Assignee: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Toshihiro Sakamoto, Takashi Mita, Kazuaki Shibata, Yoshio Ogino, Hideya Komatani
  • Publication number: 20140343038
    Abstract: The present invention provides a compound represented by the following general formula (I) or a salt thereof which has a Syk inhibitory effect (in the formula R1 represents a hydrogen atom or an optionally substituted C1-C6 alkyl group; A represents a hydrogen atom, an optionally substituted C1-C8 alkyl group, an optionally substituted C2-C6 alkenyl group, an optionally substituted C2-C6 alkynyl group, an optionally substituted C3-C10 cycloalkyl group, an optionally substituted C6-C14 aromatic hydrocarbon group, an optionally substituted 4- to 10-membered unsaturated heterocyclic group, or an optionally substituted 4- to 10-membered saturated heterocyclic group, or optionally forms a 4- to 10-membered unsaturated heterocyclic ring or a 4- to 10-membered saturated heterocyclic ring together with R1 and the nitrogen atom bonded thereto; R2 represents a hydrogen atom or an optionally substituted C1-C6 alkyl group; and B represents an optionally substituted unsaturated heterocyclic group).
    Type: Application
    Filed: September 28, 2012
    Publication date: November 20, 2014
    Applicant: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Toshihiro Sakamoto, Takashi Mita, Kazuaki Shibata, Yoshio Ogino, Hideya Komatani
  • Patent number: 8614221
    Abstract: The instant invention provides for substituted fused naphthyridine derivatives that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.
    Type: Grant
    Filed: March 10, 2010
    Date of Patent: December 24, 2013
    Assignees: Merck Sharp & Dohme Corp., MSD K.K.
    Inventors: Weiming Fan, Thomas F. N. Haxell, Matthew G. Jenks, Nobuhiko Kawanishi, Shuliang Lee, Hao Liu, Michael J. Malaska, Joseph A. Moore, III, Yoshio Ogino, Yu Onozaki, Bharathi Pandi, Michael R. Peel, Toshihiro Sakamoto, Tony Siu
  • Patent number: 8536193
    Abstract: The instant invention provides for substituted [1,2,4]triazolo[4,3-a]-1,5-naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms, preferably Akt1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity, especially Akt1 by administering the compound to a patient in need of treatment of cancer.
    Type: Grant
    Filed: May 27, 2009
    Date of Patent: September 17, 2013
    Assignees: Merck Sharp & Dohme Corp., MSD K.K.
    Inventors: Hidetomo Furuyama, Yasuhiro Goto, Nobuhiko Kawanishi, Mark E. Layton, Takashi Mita, Yoshio Ogino, Yu Onozaki, Michael A. Rossi, Toshihiro Sakamoto, Philip E. Sanderson, Jiabing Wang
  • Publication number: 20130102605
    Abstract: The instant invention provides for substituted thiazoles that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.
    Type: Application
    Filed: April 21, 2011
    Publication date: April 25, 2013
    Inventors: Peng Liang, Morihiro Mitsuya, Yoshio Ogino, Changhe Qi, Hidekazu Takahashi, Paul Tempest, Jiabing Wang, Yuguang Wang, Zhenzhen Wang, Shaohua Zhang, Nanyan Zhou, Jiuxiang Zhu
  • Patent number: 8207169
    Abstract: The compounds of Formula D are of the class of triazolo-pyrido-pyrazines which are inhibitors of AKT useful for the treatment of cancer
    Type: Grant
    Filed: May 28, 2009
    Date of Patent: June 26, 2012
    Assignee: MSD K.K.
    Inventors: Hidetomo Furuyama, Yasuhiro Goto, Nobuhiko Kawanishi, Mark E. Layton, Takashi Mita, Akira Naya, Yoshio Ogino, Yu Onozaki, Kevin J. Rodzinak, Toshihiro Sakamoto, Philip E. Sanderson, Jiabing Wang
  • Publication number: 20120004240
    Abstract: The instant invention provides for substituted fused naphthyridine derivatives that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.
    Type: Application
    Filed: March 3, 2010
    Publication date: January 5, 2012
    Inventors: Weiming Fan, Thomas F.N. Haxell, Matthew G. Jenks, Nobuhiko Kawanishi, Shuliang Lee, Hao Liu, Michael J. Malaska, Joseph A. Moore, III, Yoshio Ogino, Yu Onozaki, Bharathi Pandi, Michael R. Peel, Toshihiro Sakamoto, Tony Siu
  • Publication number: 20110288090
    Abstract: The instant invention provides for compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.
    Type: Application
    Filed: January 25, 2010
    Publication date: November 24, 2011
    Inventors: Donna J. Armstrong, Yasuhiro Goto, Takashi Hashihayata, Tetsuya Kato, Michael J. Kelly, III, Mark E. Layton, Craig W. Lindsley, Yoshio Ogino, Yu Onozaki, Kenvin J. Rodzinak, Michael A. Rossi, Philip E. Sanderson, Jiabing Wang, Melissa M. Yaroschak
  • Patent number: 7994331
    Abstract: A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: (I) wherein X1 to X4 independently represent a carbon atom or the like; the ring A represents a 5- to 6-membered heteroaryl having 1 to 4 heteroatoms independently selected from the group consisting of a nitrogen atom, a sulfur atom and an oxygen atom; X5 represents an oxygen atom or the like; X represents a carbon atom or the like; Het represents a 5- or 6-membered aliphatic heterocycle; R1 represents an aryl or the like; R2 represents a formyl group or the like; and R3 represents a —C1-6 alkyl or the like. The compound or salt has a glucokinase activation effect and is useful as a therapeutic agent for diabetes.
    Type: Grant
    Filed: July 12, 2006
    Date of Patent: August 9, 2011
    Assignee: MSD K.K.
    Inventors: Yoshio Ogino, Katsumasa Nonoshita, Teruyuki Nishimura, Jun-ichi Eiki
  • Patent number: 7932394
    Abstract: A glucokinase activator is provided; and a treatment and/or a preventive for diabetes, or a treatment and/or a preventive for diabetes such as retinopathy, nephropathy, neurosis, ischemic cardiopathy, arteriosclerosis, and further a treatment and/or a preventive for obesity are provided. The invention relates to a compound of a formula (I): [wherein R1 and R2 represent a hydrogen, etc.; R3 represents a hydrogen atom, a halogen atom, etc.; R4 each independently represents a hydrogen atom, a lower alkyl group, etc.; Q represents a carbon atom, a nitrogen atom or a sulfur atom (the sulfur atom may be mono- or di-substituted with an oxo group); R5 and R6 each represent a hydrogen atom, a lower alkyl group, etc.
    Type: Grant
    Filed: November 1, 2005
    Date of Patent: April 26, 2011
    Assignee: MSD K.K.
    Inventors: Noriaki Hashimoto, Keiji Takahashi, Chisato Nakama, Yoshio Ogino, Fumiko Sakai, Teruyuki Nishimura, Jun-ichi Eiki
  • Publication number: 20110092511
    Abstract: The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms, preferably Akt1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity especially Akt1 by administering the compound to a patient in need of treatment of cancer.
    Type: Application
    Filed: May 28, 2009
    Publication date: April 21, 2011
    Inventors: Hidetomo Furuyama, Yasuhiro Goto, Nobuhiko Kawanishi, Mark E. Layton, Takashi Mita, Akira Naya, Yoshio Ogino, Yu Onozaki, Kevin J. Rodzinak, Toshihiro Sakamoto, Philip E. Sanderson, Jiabing Wang
  • Publication number: 20110082135
    Abstract: The instant invention provides for substituted [1,2,4]triazolo[4,3-a]-1,5-naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms, preferably Akt1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity, especially Akt1 by administering the compound to a patient in need of treatment of cancer.
    Type: Application
    Filed: May 27, 2009
    Publication date: April 7, 2011
    Inventors: Hidetomo Furuyama, Yasuhiro Goto, Nobuhiko Kawanishi, Mark E. Layton, Takashi Mita, Yoshio Ogino, Yu Onozaki, Michael A. Rossi, Toshihiro Sakamoto, Philip E. Sanderson, Jiabing Wang
  • Patent number: 7803807
    Abstract: The present invention relates to compounds of Formula (I) wherein A, B and C are independently methine, said methine being optionally substituted; D is nitrogen; T, U, V and W are independently methine or nitrogen, said methine being optionally substituted and least two of T, U, V and W are said methine groups; X is —N(SO2R4)—, N(COR5)— or —CO—; Y is C(R6)(R7)—, —O— or —N(R8) and a pharmaceutically acceptable salt, ester or N-oxide derivative thereof.
    Type: Grant
    Filed: October 26, 2009
    Date of Patent: September 28, 2010
    Assignee: Banyu Pharmaceutical Co., Ltd.
    Inventors: Norikazu Otake, Minoru Moriya, Yoshio Ogino, Kenji Matsuda, Yoshikazu Nagae, Akio Kanatani, Takehiro Fukami
  • Patent number: 7799820
    Abstract: Disclosed is a compound represented by the formula (I) below, which has a glucokinase-activating effect and is thus useful for treatment of diabetes or obesity, or a pharmaceutically acceptable salt thereof. In the formula, R1 represents an aryl or the like; R11 represents an aryl or the like; R2 represents a formyl or the like, R3 represents a C1-6 alkyl or the like; R3 represents a hydrogen atom or the like; Z1 represents —O— or the like; Z2 represents —O— or the like; Y1-Y4 respectively represent a carbon atom or a nitrogen atom; ring A represents a heteroaryl group; X represents a carbon atom or the like; m represents an integer of 0-2; and q represents an integer of 0-2.
    Type: Grant
    Filed: September 29, 2006
    Date of Patent: September 21, 2010
    Assignee: Banyu Pharmaceutical Co., Ltd.
    Inventors: Keiji Takahashi, Yoshio Ogino, Teruyuki Nishimura
  • Patent number: 7728025
    Abstract: A glucokinase activator is provided; and a remedy and/or a preventive for diabetes, or a remedy and/or a preventive for diabetes such as retinopathy, nephropathy, neurosis, ischemic cardiopathy, arteriosclerosis, and further a remedy and/or a preventive for obesity are provided. A glucokinase activator characterized by containing a 2-heteroaryl-substituted benzimidazole derivative of a general formula (I-0) or its pharmaceutically-acceptable salt: [in the formula, X represents a carbon atom or a nitrogen atom; X1, X2, X3 and X4 each independently represent a carbon atom or a nitrogen atom; the ring A represents a 5- or 6-membered nitrogen-containing aromatic hetero ring of a formula (II): (in the formula, X represents a carbon atom or a nitrogen atom); R1 represents an aryl, etc.; R2 represents a hydroxy, etc.; R3 represents a —C1-6 alkyl, etc.; R4 represents a —C1-6 alkyl, etc.; X5 represents —O—, etc.
    Type: Grant
    Filed: December 28, 2004
    Date of Patent: June 1, 2010
    Assignee: Banyu Pharmaceutical Co., Ltd.
    Inventors: Katsumasa Nonoshita, Makoto Ishikawa, Hiroshi Nakashima, Daisuke Tsukahara, Yoshio Ogino, Fumiko Sakai, Yoshikazu Nagae, Keisuke Arakawa, Teruyuki Nishimura
  • Publication number: 20100087360
    Abstract: A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: (I) wherein X1 to X4 independently represent a carbon atom or the like; the ring A represents a 5- to 6-membered heteroaryl having 1 to 4 heteroatoms independently selected from the group consisting of a nitrogen atom, a sulfur atom and an oxygen atom; X5 represents an oxygen atom or the like; X represents a carbon atom or the like; Het represents a 5- or 6-membered aliphatic heterocycle; R1 represents an aryl or the like; R2 represents a formyl group or the like; and R3 represents a —C1-6 alkyl or the like. The compound or salt has a glucokinase activation effect and is useful as a therapeutic agent for diabetes.
    Type: Application
    Filed: July 12, 2006
    Publication date: April 8, 2010
    Inventors: Yoshio Ogino, Katsumasa Nonoshita, Teruyuki Nishimura, Jun-ichi Eike